MX2017004652A - Novedoso derivado de 5,6-dihidro-4h-benzo[b]tieno-[2,3-d]azepina. - Google Patents

Novedoso derivado de 5,6-dihidro-4h-benzo[b]tieno-[2,3-d]azepina.

Info

Publication number
MX2017004652A
MX2017004652A MX2017004652A MX2017004652A MX2017004652A MX 2017004652 A MX2017004652 A MX 2017004652A MX 2017004652 A MX2017004652 A MX 2017004652A MX 2017004652 A MX2017004652 A MX 2017004652A MX 2017004652 A MX2017004652 A MX 2017004652A
Authority
MX
Mexico
Prior art keywords
thieno
benzo
dihydro
novel
azepine derivative
Prior art date
Application number
MX2017004652A
Other languages
English (en)
Spanish (es)
Inventor
Kazuhiro Ito
Peter John Murray
Stuart Thomas Onions
Euan Alexander Fraser Fordyce
Fraser Hunt Simon
Sherbukhin Vladimir
William BROOKES Daniel
Original Assignee
Pulmocide Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmocide Ltd filed Critical Pulmocide Ltd
Publication of MX2017004652A publication Critical patent/MX2017004652A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2017004652A 2014-10-10 2015-10-08 Novedoso derivado de 5,6-dihidro-4h-benzo[b]tieno-[2,3-d]azepina. MX2017004652A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14188494 2014-10-10
PCT/GB2015/052944 WO2016055791A1 (en) 2014-10-10 2015-10-08 Novel 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative

Publications (1)

Publication Number Publication Date
MX2017004652A true MX2017004652A (es) 2017-06-19

Family

ID=51842340

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004652A MX2017004652A (es) 2014-10-10 2015-10-08 Novedoso derivado de 5,6-dihidro-4h-benzo[b]tieno-[2,3-d]azepina.

Country Status (13)

Country Link
US (6) US9732098B2 (Direct)
EP (2) EP3204389B1 (Direct)
JP (2) JP2017531039A (Direct)
KR (1) KR20170058921A (Direct)
CN (1) CN106852144B (Direct)
AU (1) AU2015329789B2 (Direct)
BR (1) BR112017005104B1 (Direct)
CA (1) CA2957868C (Direct)
EA (1) EA201790796A8 (Direct)
IL (1) IL250823A0 (Direct)
MX (1) MX2017004652A (Direct)
SG (1) SG11201701184WA (Direct)
WO (2) WO2016055791A1 (Direct)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2957868C (en) * 2014-10-10 2023-02-28 Pulmocide Limited Novel 5,6-dihydro-4h-benzo[b]thieno-[2,3-d]azepine derivative
WO2016097761A1 (en) 2014-12-18 2016-06-23 Pulmocide Limited 4,5-dihydro-6h-thieno[3,2-d]benzazepine derivatives and their use to treat respiratory syncytial virus (rsv) infections
PT3324977T (pt) 2015-07-22 2022-10-14 Enanta Pharm Inc Derivados de benzodiazepina como inibidores de vsr
US20170226129A1 (en) 2016-01-15 2017-08-10 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
SG11201806581TA (en) * 2016-02-03 2018-09-27 Janssen Sciences Ireland Uc Combination products for the treatment of rsv
US10626126B2 (en) * 2016-04-08 2020-04-21 Pulmocide Limited Compounds
WO2018129287A1 (en) 2017-01-06 2018-07-12 Enanta Pharmaceuticals, Inc. Heteroaryldiazepine derivatives as rsv inhibitors
JP7076459B2 (ja) 2017-02-16 2022-05-27 エナンタ ファーマシューティカルズ インコーポレイテッド ベンゾジアゼピン誘導体の製造プロセス
US10752598B2 (en) 2017-06-07 2020-08-25 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as RSV inhibitors
US10851115B2 (en) 2017-06-30 2020-12-01 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
WO2019006295A1 (en) * 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
US10881666B2 (en) 2017-09-29 2021-01-05 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as RSV inhibitors
WO2019094920A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as rsv inhibitors
US10501422B2 (en) 2017-11-13 2019-12-10 Enanta Pharmaceuticals, Inc. Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives
US10975094B2 (en) 2018-04-11 2021-04-13 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
PH12021552201A1 (en) 2019-03-18 2022-05-30 Enanta Pharm Inc Benzodiazepine derivatives as rsv inhibitors
US11179400B2 (en) 2019-04-09 2021-11-23 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
US11572367B2 (en) 2019-10-04 2023-02-07 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
WO2022010882A1 (en) * 2020-07-07 2022-01-13 Enanta Pharmaceuticals, Inc, Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
US11945830B2 (en) 2021-02-26 2024-04-02 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
US12162857B2 (en) 2022-04-27 2024-12-10 Enanta Pharmaceuticals, Inc. Antiviral compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693635A (en) 1993-07-29 1997-12-02 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
AU782404B2 (en) 1999-04-28 2005-07-28 Sanofi-Aventis Deutschland Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
WO2009089305A1 (en) * 2008-01-07 2009-07-16 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2011005842A1 (en) * 2009-07-09 2011-01-13 Gilead Sciences, Inc. Anti-rsv compounds
US9144557B2 (en) 2009-10-13 2015-09-29 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses
PT2598483T (pt) 2010-07-29 2020-10-12 Rigel Pharmaceuticals Inc Compostos heterocíclicos de ativação de ampk e métodos de utilização dos mesmos
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
EP3177299A4 (en) 2014-08-05 2018-04-04 Alios Biopharma, Inc. Combination therapy for treating a paramyxovirus
CA2957868C (en) 2014-10-10 2023-02-28 Pulmocide Limited Novel 5,6-dihydro-4h-benzo[b]thieno-[2,3-d]azepine derivative
US20170226129A1 (en) 2016-01-15 2017-08-10 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
SG11201806581TA (en) 2016-02-03 2018-09-27 Janssen Sciences Ireland Uc Combination products for the treatment of rsv
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
US10851115B2 (en) 2017-06-30 2020-12-01 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors

Also Published As

Publication number Publication date
CA2957868C (en) 2023-02-28
BR112017005104A2 (pt) 2017-12-05
US20190202841A1 (en) 2019-07-04
US10035810B2 (en) 2018-07-31
CN106852144B (zh) 2019-08-30
BR112017005104B1 (pt) 2022-08-23
US20170190718A1 (en) 2017-07-06
WO2016055791A1 (en) 2016-04-14
KR20170058921A (ko) 2017-05-29
US10273249B2 (en) 2019-04-30
AU2015329789A1 (en) 2017-03-09
US9732098B2 (en) 2017-08-15
EP3204389A1 (en) 2017-08-16
US10472375B2 (en) 2019-11-12
US9926335B2 (en) 2018-03-27
US20170355717A1 (en) 2017-12-14
US10189863B2 (en) 2019-01-29
EA201790796A1 (ru) 2017-09-29
EP3204388B1 (en) 2018-12-12
SG11201701184WA (en) 2017-03-30
EP3204389B1 (en) 2019-06-26
US20170305935A1 (en) 2017-10-26
EP3204388A1 (en) 2017-08-16
CN106852144A (zh) 2017-06-13
IL250823A0 (en) 2017-04-30
WO2016055792A1 (en) 2016-04-14
JP2017531038A (ja) 2017-10-19
EA201790796A8 (ru) 2018-10-31
JP6675407B2 (ja) 2020-04-01
US20180319820A1 (en) 2018-11-08
JP2017531039A (ja) 2017-10-19
US20180179228A1 (en) 2018-06-28
AU2015329789B2 (en) 2019-09-26
CA2957868A1 (en) 2016-04-14

Similar Documents

Publication Publication Date Title
MX2017004652A (es) Novedoso derivado de 5,6-dihidro-4h-benzo[b]tieno-[2,3-d]azepina.
IL251285A0 (en) 3-substituted 5-amino-h6-triazolo[5,4-d]pyrimidine-7,2-dione compounds for the treatment and prevention of viral infection
MX2021002168A (es) Compuestos antivirales.
PH12016500486A1 (en) Aza-pyridone compounds and uses thereof
PL3174870T3 (pl) Tieno[3,2-d]pirymidyny, furo[3,2-d]pirymidyny i pirolo[3,2- d]pirymidyny przydatne do leczenia zakażeń syncytialnym wirusem oddechowym
WO2015001504A3 (en) Antibody formulations and methods
SG11201502522WA (en) 1,2,4-triazine derivatives for the treatment of viral infections.
PH12015501993B1 (en) Pyrazole-amide compound and medicinal uses therefor
WO2015110491A3 (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
SG11201702766YA (en) Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (rsv)
SA517381678B1 (ar) مركبات داي هيدرو بيريميدين-2-أون واستخدامها الطبي
EP2601967A4 (en) MEDICINE FOR PREVENTING AND TREATING HIV-RELATED OR HIV-RELATED DISEASES, INCLUDING AIDS
IN2013MU01985A (Direct)
WO2015130547A8 (en) Bis-cyclic guanidine compound compositions, methods of use and treatment thereof
HK1220196A1 (zh) 抗病毒吲哚并[2,3-b]喹喔啉
WO2017064558A8 (ja) 新規免疫賦活化剤
WO2014177510A3 (en) Polymer conjugates of indolocarbazole compounds in the treatment of pruritus
WO2014121170A3 (en) Antiviral compounds
WO2016073652A8 (en) Iminosugars useful for the treatment of viral diseases
MX2017003415A (es) Un derivado de tetrahidropirrolo [3,4-d] [1,3]tiazina como inhibidor de bace.
DK3148588T3 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease
MX2015017276A (es) Derivados de hiperforina y su uso en la enfermedad de alzheimer.
WO2017059318A3 (en) Scaphopetalone analogs and their uses
UA98069U (xx) N-(3-ТРИФТОРМЕТИЛФЕНІЛ)-2-(2-ОКСО-3,5a,6,11b-ТЕТРАГІДРО-2Н,5Н-ХРОМЕНО[4',3':4,5]ТІОПІРАНО[2,3-d][1,3]ТІАЗОЛ-3-ІЛ)АЦЕТАМІД, ЩО ПРОЯВЛЯЄ АНАБОЛІЧНУ ТА АНДРОГЕННУ ДІЮ
HK1249425A1 (zh) 間-碘苄基胍及其前體的製劑